Lifitegrast (SAR 1118) sodium是一种有效的整合素拮抗剂，可用于干眼症的相关研究。它通过阻断淋巴细胞功能相关抗原（LFA-1）与细胞间粘附分子1（ICAM-1）的结合，从而中断T细胞介导的炎症周期。

[1] Perez VL, Pflugfelder SC, Zhang S, Shojaei A, Haque R. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. Ocul Surf. 2016 Apr;14(2):207-15. doi: 10.1016/j.jtos.2016.01.001. Epub 2016 Jan 22. PMID: 26807723.[2]Sun Y, Zhang R, Gadek TR, O'Neill CA, Pearlman E. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther. 2013 May;29(4):395-402. doi: 10.1089/jop.2012.0102. Epub 2012 Dec 5. PMID: 23215542; PMCID: PMC3643258.